Table of Contents
ISRN Pathology
Volume 2011 (2011), Article ID 817618, 4 pages
http://dx.doi.org/10.5402/2011/817618
Clinical Study

Clinical Usefulness of Cancer Markers in Primary Breast Cancer

1Department of Gynecology, Hospital of the Johann Wolfgang Goethe University, Frankfurt/Main 60431, Germany
2Department of Pathology, Wroclaw Medical University, 50-367 Wroclaw, Poland
3Department of Laboratory Medicine, Hospital of the Johann Wolfgang Goethe University, Frankfurt/Main 60431, Germany

Received 16 August 2011; Accepted 27 September 2011

Academic Editors: V. J. Amatya, A. Pagani, and A.-G. Selim

Copyright © 2011 A. Verring et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The aim of this study was to investigate the diagnostic power of CA 549, MSA and CA 15-3 in identifying breast cancer. The study included 232 patients of which 56 were healthy, 43 had benign breast cancer and 191 with other growths. The results were obtained using a specific immunoassay and using producers' cut offs. The following sensitivity and specificity of markers were found: CA 549 (sen.: 40%/spec.: 90%), MSA (sen.: 22%/spec.: 96%), and CA 15-3 (sen.: 33%/spec.: 86%). Ideal cut offs were defined with ROC curves. A significant correlation was found between CA 549, MSA, and CA 15-3. The combination of markers does not improve the clinical usefulness to identify only breast cancer. Serum tumor markers are abnormally elevated in patients with breast cancer. CA 549, MSA, CA 15-3 are useful clinical markers, good indicators of disease extent, and may have important prognostic value. This study demonstrates the role of the tumor markers in breast cancer.